Comparative Pharmacology
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus SIMVASTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus SIMVASTATIN.
ATORVASTATIN CALCIUM vs SIMVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, increases LDL receptor expression, and lowers plasma LDL cholesterol.
10-80 mg orally once daily, starting at 10-20 mg; maximum dose 80 mg/day.
10-40 mg orally once daily in the evening; maximum 80 mg/day.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 11–24 h); the active metabolite half-life is 20–30 h; clinical context: supports once-daily dosing despite shorter HMG-CoA reductase inhibitory half-life due to prolonged pharmacodynamic effect.
Clinical Note
moderateSimvastatin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Simvastatin."
Clinical Note
moderateSimvastatin + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Simvastatin."
Clinical Note
moderateSimvastatin + Prednisolone
"The serum concentration of Prednisolone can be increased when it is combined with Simvastatin."
Clinical Note
moderateSimvastatin + Resveratrol
The terminal elimination half-life of simvastatin is approximately 2-3 hours, but for the active metabolite (simvastatin acid) it is about 1.9 hours; clinical lipid-lowering effects persist longer due to sustained HMG-CoA reductase inhibition.
Primarily biliary excretion (approx. 70%) as metabolites; renal excretion accounts for <2% of the administered dose; fecal elimination of metabolites and parent drug (approx. 90%).
Primarily hepatic metabolism, with approximately 13% excreted in urine as metabolites and 60% in feces via biliary elimination; less than 0.5% of the active form is excreted unchanged in urine.
Category C
Category D/X
Statin
Statin
"The serum concentration of Resveratrol can be increased when it is combined with Simvastatin."